Stock Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead Announces Phase 3 Results for Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenamide (TAF)

[Business Wire] – Gilead Sciences, Inc. today announced detailed 48-week results from two Phase 3 studies evaluating its investigational once-daily single tablet regimen containing tenofovir alafenamide for the treatment of HIV-1 infection in . . . → Read More: Stock Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead Announces Phase 3 Results for Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenamide (TAF) Similar Articles: Company Update (NYSE:LLY): Lilly delays submission to market once-daily diabetes drug Company Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead Sciences to Present at Two Upcoming Investor Conferences Stock Update (NASDAQ:GILD): Gilead Sciences Announces Third Quarter 2014 Financial Results
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.